DEARGEN Inc. products

DearDTI presents drug candidates with a good efficacy by predicting the binding affinity, based on information about the compound-protein interactions.

Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new disease targets with Dr.UG and further realizes precision medicine by designing small molecules for new drugs.

WX presents biomarkers, based on raw transcriptome data. It is an artificial intelligence technology that can predict biomarkers, prognostic biomarkers and even the mode of action (MOA) of disease targets.

Agonist refers to substances that activate a specific target protein. It can easily be viewed as the opposite of inhibitor. Until now, Deargen`s drug-target interaction (DTI) was predicted based on the binding affinity between the substance and the target protein, which causes barrier to distinguish between the inhibition and activation activity. In addition, the demand for agonist hit discovery is on the rise in the field of new drug development. To address these unmet needs, Deargen developed DearDTE (Drug-Target Efficacy), which can predict the activation of substances and target proteins. DearDTE is currently being used in cooperation with various partners such as SK Chemical, IN Therapeutics, Amyloid Solution, and Pohang University of Science and Technology

MolEQ designs novel compounds by optimizing multiple properties such as efficacy and toxicity of a lead compound.